Shopping Cart 0
Cart Subtotal
USD 0

Graft Versus Host Disease (GVHD)-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Graft Versus Host Disease (GVHD)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD)-Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 23, 11, 35, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 2 molecules, respectively.

Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology).

The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Graft Versus Host Disease (GVHD)-Overview 6

Graft Versus Host Disease (GVHD)-Therapeutics Development 7

Graft Versus Host Disease (GVHD)-Therapeutics Assessment 22

Graft Versus Host Disease (GVHD)-Companies Involved in Therapeutics Development 34

Graft Versus Host Disease (GVHD)-Drug Profiles 65

Graft Versus Host Disease (GVHD)-Dormant Projects 369

Graft Versus Host Disease (GVHD)-Discontinued Products 373

Graft Versus Host Disease (GVHD)-Product Development Milestones 374

Appendix 385


List Of Figure

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by AbbVie Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by AbGenomics International Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Allergan Plc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Amunix Operating Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by AnaptysBio Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by apceth Biopharma GmbH, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Aptevo Therapeutics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by arGEN-X BV, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Athersys Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Bio-Cancer Treatment International Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Biogen Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Bristol-Myers Squibb Company, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Capricor Therapeutics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Cell2B Advanced Therapeutics SA, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by CellECT Bio Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Commence Bio Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Cynata Therapeutics Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Cytodyn Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Dr. Falk Pharma GmbH, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Escape Therapeutics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Fate Therapeutics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Generon (Shanghai) Corp Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Gilead Sciences Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by GlaxoSmithKline Plc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Incyte Corp, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Jazz Pharmaceuticals Plc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Kadmon Corp LLC, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Kamada Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Kiadis Pharma NV, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Kymab Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by MacroGenics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Mallinckrodt Plc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Mesoblast Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Nektar Therapeutics, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Nohla Therapeutics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Novartis AG, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by OncoImmune Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by OSE Immunotherapeutics, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Pfizer Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Pharmicell Co Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by REGiMMUNE Corp, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Sanofi, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Sarepta Therapeutics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Seattle Genetics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Seres Therapeutics Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Sigmoid Pharma Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Synedgen Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Targazyme Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by TC BioPharm Ltd, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by TxCell SA, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by United BioPharma Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Vault Pharma Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by VBI Vaccines Inc, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by Xenikos BV, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by XL-protein GmbH, H1 2017

Graft Versus Host Disease (GVHD)-Pipeline by ZIOPHARM Oncology Inc, H1 2017

Graft Versus Host Disease (GVHD)-Dormant Projects, H1 2017

Graft Versus Host Disease (GVHD)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Graft Versus Host Disease (GVHD)-Dormant Projects, H1 2017 (Contd..2), H1 2017

Graft Versus Host Disease (GVHD)-Dormant Projects, H1 2017 (Contd..3), H1 2017

Graft Versus Host Disease (GVHD)-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AbbVie Inc, AbGenomics International Inc, Allergan Plc, Amunix Operating Inc, AnaptysBio Inc, apceth Biopharma GmbH, Aptevo Therapeutics Inc, arGEN-X BV, Athersys Inc, Bellicum Pharmaceuticals Inc, Bio-Cancer Treatment International Ltd, Biogen Inc, Bristol-Myers Squibb Company, Capricor Therapeutics Inc, Cell2B Advanced Therapeutics SA, CellECT Bio Inc, Commence Bio Inc, Cynata Therapeutics Ltd, Cytodyn Inc, Dr. Falk Pharma GmbH, Escape Therapeutics Inc, F. Hoffmann-La Roche Ltd, Fate Therapeutics Inc, Generon (Shanghai) Corp Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, Incyte Corp, Jazz Pharmaceuticals Plc, Kadmon Corp LLC, Kamada Ltd, Kiadis Pharma NV, Kymab Ltd, Kyorin Pharmaceutical Co Ltd, MacroGenics Inc, Mallinckrodt Plc, Mesoblast Ltd, Millennium Pharmaceuticals Inc, Nektar Therapeutics, Nohla Therapeutics Inc, Novartis AG, OncoImmune Inc, OSE Immunotherapeutics, Pfizer Inc, Pharmicell Co Ltd, REGiMMUNE Corp, Sanofi, Sarepta Therapeutics Inc, Seattle Genetics Inc, Seres Therapeutics Inc, Sigmoid Pharma Ltd, Synedgen Inc, Takeda Pharmaceutical Company Ltd, Targazyme Inc, TC BioPharm Ltd, TxCell SA, United BioPharma Inc, Vault Pharma Inc, VBI Vaccines Inc, Xenikos BV, XL-protein GmbH, ZIOPHARM Oncology Inc